Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 15/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821050 | 0.86 | KIF11 (0.42) | KIF11PIK3CDHDAC1HDAC6MAPT | |
| SCHEMBL5764538 | 0.77 | HPGD (0.39) | KIF11MAPT | |
| SCHEMBL5821082 | 0.73 | KIF11 (0.55) | KIF11 | |
| SCHEMBL12454692 | 0.71 | CACNA2D1 (0.48) | KIF11MAPT | |
| SCHEMBL5100450 | 0.71 | MEN1 (0.45) | KIF11MAPT | |
| SCHEMBL3837879 | 0.71 | MEN1 (0.41) | KIF11MAPT | |
| SCHEMBL4069383 | 0.70 | MEN1 (0.40) | KIF11PIK3CDHDAC1HDAC6MAPT | |
| SCHEMBL5103886 | 0.70 | KIF11 (0.53) | KIF11MAPT | |
| SCHEMBL5354342 | 0.70 | KIF11 (0.41) | KIF11 | |
| SCHEMBL6518712 | 0.69 | KIF11 (0.54) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | COLEMAN PAUL J | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234080-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIFC1 | KIF11 9/4885EGLN1 3381/4885PIK3CD 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.